Abstract Fecal Immunochemical Test (FIT) followed by a colonoscopy is an efficacious strategy to improve the adenoma detection rate and Colorectal Cancer (CRC). There is no organized national screening program for CRC in Brazil. The aim of this research was to describe the implementation of an organized screening program for CRC through FIT followed by colonoscopy, in an urban low-income community of São Paulo city. The endpoints of the study were: FIT participation rate, FIT positivity rate, colonoscopy compliance rate, Positive Predictive Values (PPV) for adenoma and CRC, and the rate of complications. From May 2016 to October 2019, asymptomatic individuals, 50-75 years old, received a free kit to perform the FIT. Positive FIT (≥ 50 ng/mL) individuals were referred to colonoscopy. 10,057 individuals returned the stool sample for analysis, of which (98.2%) 9,881 were valid. Women represented 64.8% of the participants. 55.3% of individuals did not complete elementary school. Positive FIT was 7.8% (776/9881). The colonoscopy compliance rate was 68.9% (535/776). There were no major colonoscopy complications. Adenoma were detected in 63.2% (332/525) of individuals. Advanced adenomatous lesions were found in 31.4% (165/525). CRC was diagnosed in 5.9% (31/525), characterized as adenocarcinoma: in situ in 3.2% (1/31), intramucosal in 29% (9/31), and invasive in 67.7% (21/31). Endoscopic treatment with curative intent for CRC was performed in 45.2% (14/31) of the cases. Therefore, in an urban low-income community, an organized CRC screening using FIT followed by colonoscopy ensued a high participation rate, and high predictive positive value for both, adenoma and CRC. (FIT . (CRC) Brazil lowincome low income city PPV (PPV complications 201 2019 5075 75 50-7 old ≥ ( 5 ng/mL ngmL ng mL 10057 10 057 10,05 analysis 98.2% 982 98 2 (98.2% 9881 9 881 9,88 valid 648 64 8 64.8 participants 553 55 3 55.3 school 78 7 7.8 776/9881. 7769881 776/9881 776 (776/9881) 689 68 68.9 535/776. 535776 535/776 535 (535/776) 632 63 63.2 332/525 332525 332 525 (332/525 314 31 4 31.4 165/525. 165525 165/525 165 (165/525) 59 5.9 31/525, 31525 31/525 , (31/525) adenocarcinoma 32 3.2 1/31, 131 1/31 1 (1/31) 29 9/31, 931 9/31 (9/31) 677 67 67.7 21/31. 2131 21/31 21 (21/31) 452 45 45.2 14/31 1431 14 (14/31 cases Therefore both (CRC 20 507 50- 1005 05 10,0 98.2 (98.2 988 88 9,8 6 64. 55. 7. 776988 776/988 77 (776/9881 68. 53577 535/77 53 (535/776 63. 332/52 33252 33 52 (332/52 31. 16552 165/52 16 (165/525 5. 3152 31/52 (31/525 3. 13 1/3 (1/31 93 9/3 (9/31 67. 213 21/3 (21/31 45. 14/3 143 (14/3 100 0 10, 98. (98. 9, 77698 776/98 (776/988 5357 535/7 (535/77 332/5 3325 (332/5 1655 165/5 (165/52 315 31/5 (31/52 1/ (1/3 9/ (9/3 21/ (21/3 14/ (14/ (98 7769 776/9 (776/98 535/ (535/7 332/ (332/ 165/ (165/5 31/ (31/5 (1/ (9/ (21/ (14 (9 776/ (776/9 (535/ (332 (165/ (31/ (1 (21 (776/ (535 (33 (165 (31 (2 (776 (53 (3 (16 (77 (5 (7